PAVmed (NASDAQ:PAVM) Price Target Lowered to $19.00 at Ascendiant Capital Markets

PAVmed (NASDAQ:PAVM) had its price target decreased by investment analysts at Ascendiant Capital Markets from $21.00 to $19.00 in a report issued on Monday,Benzinga reports. The firm currently has a “buy” rating on the stock.

PAVmed Stock Performance

Shares of NASDAQ:PAVM opened at $0.97 on Monday. PAVmed has a 52-week low of $0.60 and a 52-week high of $4.44. The business’s 50 day simple moving average is $1.08 and its two-hundred day simple moving average is $1.06. The firm has a market cap of $10.74 million, a P/E ratio of -0.22 and a beta of 0.67.

PAVmed Company Profile

PAVmed Inc focuses on acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck.